 Geron NASDAQ:GERN was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Wednesday, Zacks.com reports. The brokerage presently has a 2.00 price target on the biopharmaceutical companys stock. Zacks Investment Researchs target price suggests a potential upside of 6.38 from the companys previous close. According ... 